NCT01853085 - A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons | Biotech Hunter

Enrollment

1,830

Participants

Timeline

Start Date

April 1, 2013

Primary Completion Date

March 1, 2014

Study Completion Date

March 1, 2014

Conditions

Glaucoma, Primary Open AngleOcular Hypertension

Interventions

DRUG

Bimatoprost Ophthalmic Solution

Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan® UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks.

Trial Locations (1)

Unknown

Wiesloch